Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 11/20 | 0.55 |
| ▸ | GUCY1A1 | Q02108 | 7/20 | 0.50 |
| ▸ | GUCY1B1 | Q02153 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380310 | 1.00 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL29378676 | 1.00 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL30298890 | 1.00 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6216180 | 0.96 | ADORA3 (0.55) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6218288 | 0.96 | ADORA3 (0.55) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6219289 | 0.95 | ADORA3 (0.54) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15087495 | 0.89 | PDE5A (0.57) | ADORA3KCNH2PDE5A | |
| SCHEMBL20682623 | 0.88 | ADORA3 (0.57) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6218458 | 0.87 | ADORA3 (0.61) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6214026 | 0.87 | BUB1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790546-B1 | NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | BAYER AG (DE) | 2024-08-21 | — | — | EP | claimed |
| CN-112105358-B | Non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscle or neuromuscular diseases | 拜耳公司 | 2023-10-13 | — | — | CN | claimed |
| US-11439628-B2 | Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | claimed |
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | claimed |
| US-20210121447-A1 | The Use of Non-Steroidal Mineralocorticoid Receptor Antagonists Alone or in Combination for the Treatment of Muscular or Neuromuscular Diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-29 | — | — | US | claimed |
| EP-3790546-A1 | THE USE OF NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ALONE OR IN COMBINATION FOR THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | Bayer Aktiengesellschaft (DE) | 2021-03-17 | — | — | EP | claimed |
| CN-112105358-A | Non-steroidal mineralocorticoid receptor antagonists for use alone or in combination in the treatment of muscular or neuromuscular diseases | 拜耳公司 | 2020-12-18 | — | — | CN | claimed |
| WO-2020150698-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-23 | — | — | WO | claimed |
| US-10568895-B2 | Methods and materials for treating calcific aortic valve stenosis | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-02-25 | — | — | US | claimed |
| WO-2015011086-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-29 | — | — | WO | claimed |
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-07 | — | — | US | claimed |
| EP-2531187-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | Bayer Intellectual Property GmbH (DE) | 2012-12-12 | — | — | EP | claimed |
| WO-2011095534-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | claimed |
| US-20050255178-A1 | Enhancing the effectiveness of an inhaled therapeutic gas | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-11-17 | — | — | US | claimed |
| WO-2005077005-A2 | ENHANCING THE EFFECTIVENESS OF AN INHALED THERAPEUTIC GAS | THE GENERAL HOSPITAL CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | claimed |
| US-20050059660-A1 | activators of soluble guanylate cyclase, and inhibitors of angiotensin converting enzyme such as benazepril; treatment of cardiovascular or metabolic disorders | PHARMACIA & UPJOHN COMPANY | 2005-03-17 | — | — | US | claimed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | PDE5A, PDE3B, PDE3A | ADORA3 1626/4885KCNH2 1362/4885PDE5A 1/4885 |
| US-11439628-B2 | Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases | MC2R, NR3C2, NR3C1 | ADORA3 1773/4885KCNH2 2108/4885PDE5A 7/4885 |
| US-20210121447-A1 | The Use of Non-Steroidal Mineralocorticoid Receptor Antagonists Alone or in Combination for the Treatment of Muscular or Neuromuscular Diseases | MC2R, NR3C2, NR3C1 | ADORA3 1580/4885KCNH2 1905/4885PDE5A 5/4885 |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | PYGB, PRKG1, ACHE | ADORA3 427/4885KCNH2 1780/4885PDE5A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.